Radiologix slides in 2Q

Article

Service fees fell 9.1% in the second quarter for Radiologix, a national provider of diagnostic imaging services, to $65 million versus $71.5 million for the second quarter ended June 30. The drop was due primarily to reduced patient volume related to

Service fees fell 9.1% in the second quarter for Radiologix, a national provider of diagnostic imaging services, to $65 million versus $71.5 million for the second quarter ended June 30. The drop was due primarily to reduced patient volume related to increased competition in key markets. The numbers were up about 1%, however, compared with the previous quarter, during which Radiologix generated $64.4 million in service fees. The company achieved net income of $276,000 for the second quarter of 2003, compared with net income of $4.8 million for the previous year period and a net loss of $4.6 million for first quarter 2003. Company executives view the sequential improvement as evidence of stabilization in Radiologix' core business. Net income improved partly as a result of cost-cutting measures.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.